TANNQUILYNNE
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

TANNQUILYNNE Trademark

Serial Number: 88167507 • Registration: 6351061

TANNQUILYNNE is a trademark filed by SyneuRx International (Taiwan) Corp. on October 24, 2018. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

SyneuRx International (Taiwan) Corp. (10 trademarks)

20F.-10, No.99, Sec. 1
New Taipei City 221 , TW

Entity Type: 03

Trademark Details

Filing Date

October 24, 2018

Registration Date

May 18, 2021

Published for Opposition

March 2, 2021

Goods & Services

Syrups for pharmaceutical purposes for the treatment of Hyperglycemia, diabetes, prediabetes, insulin resistance, diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar nonketotic syndrome (HHNS), Hyperthyroidism, Polyphagia, polydipsia, polyuria, glycosuria, increased thirst and a frequent need to Urinate, coma, abdominal pain, poor wound healing, Stomach and intestinal problems such as chronic constipation or diarrhea, Worse vision, Damage to eyes, blood vessels, or kidneys, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, hypertension, heart disease, heart attack, stroke, thrombosis, fatty liver, liver cirrhosis, hyperuricemia, gout, pain in joints, joint stiffness, redness and swelling, Autism, Asperger's disorder, panic disorder, post-traumatic stress disorder, pain, childhood learning disorder, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, mania, obsessive compulsive disorder, and other diseases or symptoms related to CNS disorder, metabolic disorder, or diabetes; Pharmaceutical preparations for the treatment of Hyperglycemia, diabetes, prediabetes, insulin resistance, diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar nonketotic syndrome (HHNS), Hyperthyroidism, Polyphagia, polydipsia, polyuria, glycosuria, increased thirst and a frequent need to Urinate, coma, abdominal pain, poor wound healing, Stomach and intestinal problems such as chronic constipation or diarrhea, Worse vision, Damage to eyes, blood vessels, or kidneys, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, hypertension, heart disease, heart attack, stroke, thrombosis, fatty liver, liver cirrhosis, hyperuricemia, gout, pain in joints, joint stiffness, redness and swelling, Autism, Asperger's disorder, panic disorder, post-traumatic stress disorder, pain, childhood learning disorder, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, mania, obsessive compulsive disorder, and other diseases or symptoms related to CNS disorder, metabolic disorder, or diabetes; Pharmaceutical preparations for the treatment and prevention of Hyperglycemia, diabetes, prediabetes, insulin resistance, diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar nonketotic syndrome (HHNS), Hyperthyroidism, Polyphagia, polydipsia, polyuria, glycosuria, increased thirst and a frequent need to Urinate, coma, abdominal pain, poor wound healing, Stomach and intestinal problems such as chronic constipation or diarrhea, Worse vision, Damage to eyes, blood vessels, or kidneys, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, hypertension, heart disease, heart attack, stroke, thrombosis, fatty liver, liver cirrhosis, hyperuricemia, gout, pain in joints, joint stiffness, redness and swelling, Autism, Asperger's disorder, panic disorder, post-traumatic stress disorder, pain, childhood learning disorder, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, mania, obsessive compulsive disorder, and other diseases or symptoms related to CNS disorder, metabolic disorder, or diabetes; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Transdermal patches for use in the treatment of Hyperglycemia, diabetes, prediabetes, insulin resistance, diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar nonketotic syndrome (HHNS), Hyperthyroidism, Polyphagia, polydipsia, polyuria, glycosuria, increased thirst and a frequent need to Urinate, coma, abdominal pain, poor wound healing, Stomach and intestinal problems such as chronic constipation or diarrhea, Worse vision, Damage to eyes, blood vessels, or kidneys, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, hypertension, heart disease, heart attack, stroke, thrombosis, fatty liver, liver cirrhosis, hyperuricemia, gout, pain in joints, joint stiffness, redness and swelling, Autism, Asperger's disorder, panic disorder, post-traumatic stress disorder, pain, childhood learning disorder, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, mania, obsessive compulsive disorder, and other diseases or symptoms related to CNS disorder, metabolic disorder, or diabetes; Natural dietary supplements for the treatment of Hyperglycemia, diabetes, prediabetes, insulin resistance, diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar nonketotic syndrome (HHNS), Hyperthyroidism, Polyphagia, polydipsia, polyuria, glycosuria, increased thirst and a frequent need to Urinate, coma, abdominal pain, poor wound healing, Stomach and intestinal problems such as chronic constipation or diarrhea, Worse vision, Damage to eyes, blood vessels, or kidneys, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, hypertension, heart disease, heart attack, stroke, thrombosis, fatty liver, liver cirrhosis, hyperuricemia, gout, pain in joints, joint stiffness, redness and swelling, Autism, Asperger's disorder, panic disorder, post-traumatic stress disorder, pain, childhood learning disorder, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, mania, obsessive compulsive disorder, and other diseases or symptoms related to CNS disorder, metabolic disorder, or diabetes

Filing History

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
May 18, 2026 REM1
REGISTERED-PRINCIPAL REGISTER
May 18, 2021 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 2, 2021 NPUB
PUBLISHED FOR OPPOSITION
Mar 2, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 10, 2021 NONP
CASE RETURNED TO EXAMINATION
Dec 31, 2020 OTHE
NOTICE OF ALLOWANCE CANCELLED
Dec 31, 2020 IUCN
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 29, 2020 EXRA
ATTORNEY REVIEW/DECISION ON AMENDMENT REQUIRED
Oct 28, 2020 ATRQ
PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
Oct 28, 2020 PCBG
SOU EXTENSION 3 GRANTED
Oct 28, 2020 EX3G
ASSIGNED TO PETITION STAFF
Oct 18, 2020 APET
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Sep 18, 2020 AITU
SOU EXTENSION 3 FILED
Sep 10, 2020 EXT3
SOU TEAS EXTENSION RECEIVED
Sep 10, 2020 EEXT
TEAS PETITION TO AMEND BASIS RECEIVED
Sep 10, 2020 TPAD
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jul 24, 2020 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 24, 2020 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Jul 24, 2020 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 24, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 24, 2020 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jul 24, 2020 COAR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 29, 2020 EXRA
SOU EXTENSION 2 GRANTED
Feb 27, 2020 EX2G
SOU EXTENSION 2 FILED
Feb 27, 2020 EXT2
SOU TEAS EXTENSION RECEIVED
Feb 27, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 15, 2019 EXRA
SOU EXTENSION 1 GRANTED
Aug 13, 2019 EX1G
SOU EXTENSION 1 FILED
Aug 13, 2019 EXT1
SOU TEAS EXTENSION RECEIVED
Aug 13, 2019 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar 12, 2019 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 15, 2019 NPUB
PUBLISHED FOR OPPOSITION
Jan 15, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 26, 2018 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 7, 2018 CNSA
ASSIGNED TO EXAMINER
Dec 7, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 6, 2018 NWOS
NEW APPLICATION ENTERED
Oct 27, 2018 NWAP